The Southeast Asia Medical Tourism Wave to China: Why 150,000+ Patients Made the Trip in 2025

Of all the trends I've watched in China's medical tourism boom over the past two years, the surge from Southeast Asia is the most striking — and the least reported in English-language media.

In 2025, over 150,000 patients from Southeast Asian countries — Indonesia, Malaysia, Vietnam, Thailand, the Philippines, Myanmar, Cambodia, Laos, and Singapore — traveled to China for medical treatment. That's a 73.6% increase from three years ago. At Hainan's Boao Lecheng Medical Pilot Zone alone, patients from Southeast Asia accounted for over 60% of international visits, with year-on-year growth of 800% in Q1 2026.

This isn't a trickle — it's a wave. And understanding why tells you a lot about where China's medical tourism industry is headed.

Why Southeast Asian Patients Are Choosing China

Based on conversations with hospital international departments and patients themselves, several factors drive this trend:

1. Geographic Proximity

Kunming in Yunnan Province is a 2-hour flight from Bangkok, 3 hours from Kuala Lumpur, and 4 hours from Jakarta. Guangzhou and Shenzhen are equally accessible. For many Southeast Asian patients, traveling to China for treatment takes less time than flying to their own country's capital city.

Kunming has emerged as a particularly important hub. The city's medical facilities, combined with Yunnan's mild climate and lower costs, make it an attractive option for patients from Myanmar, Laos, Cambodia, and Thailand. Bangladeshi patients, diverted from India due to political tensions, are increasingly choosing Kunming for spinal surgery and other procedures at prices as low as $1,400.

2. Cost Advantage Over Regional Alternatives

For many procedures, China is now cheaper than or comparable to Singapore and Thailand — and significantly cheaper than what some ASEAN patients face at home.

A comprehensive health checkup that costs $500–$1,000 in Singapore runs $200–$500 in China. Cancer treatment at Boao Lecheng, with access to drugs not yet approved elsewhere in Asia, often costs 40–60% less than equivalent treatment in Singapore or Thailand. Even with travel costs factored in, the savings are substantial.

3. Access to Advanced Treatments

Boao Lecheng is a major draw. This special medical zone in Hainan allows patients to access drugs and medical devices approved overseas before they're approved in China — and often before they're available anywhere in Asia. As of mid-2026, over 560 innovative drugs and devices have been introduced through the zone, including CAR-T therapies, advanced immunotherapy drugs, and cutting-edge medical devices.

For Southeast Asian patients facing limited treatment options at home — particularly for cancer, rare diseases, and complex conditions — Boao Lecheng offers a genuine alternative.

4. Visa-Free and Simplified Entry

China's expanding visa-free policies have significantly reduced the friction of traveling for medical treatment. Citizens of most ASEAN countries can now enter China without a visa for stays of 15–30 days, which covers most routine medical procedures. The 240-hour (10-day) transit visa-free policy, available at 65 ports of entry, is being used by many medical tourists for short-term treatment trips.

For Boao Lecheng specifically, a 48-hour expedited medical visa is available, making last-minute treatment trips feasible.

Most Popular Treatments Among SEA Patients

• Cancer treatment:#1 reason SEA patients come to China, especially for access to CAR-T therapy, proton therapy, and immunotherapy drugs at Boao Lecheng. Hospital partners include Hainan Boao Super Hospital and the First Affiliated Hospital of Hainan Medical University.
• Health checkups: Comprehensive health screenings at 50–70% less than Singapore or Hong Kong prices. Many patients combine a checkup with a vacation in Hainan or Yunnan.
• Pediatric care: Growing rapidly, with hospitals like Shenzhen Children's Hospital (over 100,000 cross-border pediatric patients since 2023) and Zhejiang University Children's Hospital seeing increasing numbers from Indonesia, Malaysia, and Singapore.
• TCM and wellness: Particularly popular with Indonesian and Malaysian patients of Chinese descent, who are familiar with TCM concepts and seek treatment at established TCM hospitals.
• Cosmetic surgery: Smaller but growing segment. China's cosmetic surgery is more expensive than Korea's but offers better post-op follow-up access for SEA patients due to geographic proximity.
• Cardiac and orthopedic surgery: Increasing numbers from Vietnam, Myanmar, and Cambodia, where local options are limited or expensive.

Country-Specific Trends

• Indonesia: The largest SEA source market. Strong demand for cancer treatment, health checkups, and TCM. Jakarta-Haikou (Boao) direct flights make Hainan the preferred destination.
• Malaysia: Malaysia has its own strong healthcare system, but patients come to China for TCM, cancer treatment, and access to drugs not available in Malaysia. The Chinese diaspora connection is strong here.
• Vietnam: Rapid growth in border-area medical tourism to Yunnan and Guangxi. Popular treatments: health checkups, dental care, and minor surgeries.
• Myanmar: Kunming is the top destination. Patients come for spinal surgery, cancer treatment, and general medical care, often diverted from India due to visa restrictions.
• Singapore: Surprisingly active market for its size. Patients come for CAR-T therapy (where Singapore has limited options), organ transplantation, and TCM.
• Thailand: The smallest SEA source market because Thailand's own medical tourism industry is so strong. The flow is mostly Chinese patients going to Thailand, not the reverse.

Real Patient Story

A patient from Indonesia with advanced cancer was told by doctors in Jakarta that treatment options were limited. Through a family connection, she learned about Boao Lecheng. Within two weeks, she had sent her medical records, received a treatment plan, obtained a visa, and flown to Hainan. The treatment she received — a combination of immunotherapy and targeted therapy — was not yet available in Indonesia. After three months, her tumors had significantly reduced. Her total cost, including all treatment, accommodation, and flights, was less than what she'd been quoted for limited treatment options in Singapore.

Stories like this are becoming routine rather than exceptional. For many Southeast Asian patients, China is no longer a backup option — it's the first choice.

The Future

China's medical tourism infrastructure for Southeast Asian patients is still developing. Language support, payment systems, and post-discharge follow-up all need improvement. But the trajectory is clear: with over 150,000 SEA patients already coming annually, and Boao Lecheng experiencing 800% growth, this is a trend that's only accelerating.

For Southeast Asian patients considering medical treatment abroad, China offers a combination of geographic proximity, advanced medical technology, and cost competitiveness that no other destination can match. The wave is real, and it's just getting started.